Skip to Content
Merck
CN
  • Palmitate-induced skeletal muscle insulin resistance does not require NF-κB activation.

Palmitate-induced skeletal muscle insulin resistance does not require NF-κB activation.

Cellular and molecular life sciences : CMLS (2010-09-08)
Pascal P H Hommelberg, Jogchum Plat, Lauren M Sparks, Annemie M W J Schols, Anon L M van Essen, Marco C J M Kelders, Denis van Beurden, Ronald P Mensink, Ramon C J Langen
ABSTRACT

Palmitate activates the NF-κB pathway, and induces accumulation of lipid metabolites and insulin resistance in skeletal muscle cells. Little information is available whether and how these processes are causally related. Therefore, the objectives were to investigate whether intra-cellular lipid metabolites are involved in FA-induced NF-κB activation and/or insulin resistance in skeletal muscle and to investigate whether FA-induced insulin resistance and NF-κB activation are causally related. Inhibiting DGAT or CPT-1 by using, respectively, amidepsine or etomoxir increased DAG accumulation and sensitized myotubes to palmitate-induced insulin resistance. While co-incubation of palmitate with etomoxir increased NF-κB transactivation, co-incubation with amidepsine did not, indicating that DAG accumulation is associated with insulin resistance but not with NF-κB activation. Furthermore, pharmacological or genetic inhibition of the NF-κB pathway could not prevent palmitate-induced insulin resistance. In conclusion, we have demonstrated that activation of the NF-κB pathway is not required for palmitate-induced insulin resistance in skeletal muscle cells.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Insulin human, recombinant, expressed in yeast (proprietary host)
Sigma-Aldrich
Insulin human, ≥95% (HPLC), semisynthetic, powder, non-sterile
Sigma-Aldrich
Insulin human, recombinant, expressed in yeast, γ-irradiated, suitable for cell culture
Sigma-Aldrich
Insulin human, meets USP testing specifications